Methods for Treating Pressure Induced Optic Neuropathy, Preventing Neuronal Degeneration and Promoting Neuronal Cell Survival Via Administration of Lingo-1 Antagonists and TrkB Agonists
AssigneeBiogen MA Inc.
InventorSha Mi
Life of this patent
Estimating the term…
Abstract
This invention relates to methods for promoting neuronal survival and regeneration using LINGO-1 antagonists and TrkB agonists. Additionally, the invention relates to methods for treating pressure induced optic neuropathies using LINGO-1 antagonists. The invention also relates generally to methods for increasing TrkB activity and inhibiting JNK pathway signaling using a LINGO-1 antagonist.
Claims28
1-7. (canceled)
A method for promoting survival of retinal ganglion cells in a human subject displaying signs or symptoms of a pressure induced ocular neuropathy, the method comprising administering to the human subject a therapeutically effective amount of a combination of a LINGO-1 antagonist and a TrkB agonist.
-10. (canceled)
-31. (canceled)
(canceled)
-36. (canceled)
-71. (canceled)
-78. (canceled)
-107. (canceled)
A method for treating glaucoma comprising administering to a human subject in need thereof a therapeutically effective amount of a LRR and Ig domain-containing Nogo receptor-interacting protein-1 (LINGO-1;
- SEQ ID NO:2) antagonist and a Neurotrophic tyrosine kinase receptor B (TrkB) agonist, wherein the TrkB agonist is a TrkB agonist antibody or antigen-binding fragment thereof.
The method of claim 7 wherein at least one of the LINGO-1 antagonist or TrkB agonist is administered directly into the eye.
Dependencies are inferred from the claim text.